Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Tuesday, Stifel analysts maintained a Hold rating on Ionis Pharmaceuticals (NASDAQ:IONS), with a price target of $38.00. According to InvestingPro data, the stock currently trades at $33.51, with analyst targets ranging from $37 to $83. The company commands a market capitalization of $5.3 billion, though it currently operates at a loss with negative earnings per share of $3.00. During a recent Biotech Bus Tour, discussions with Ionis executives revealed several key insights into the company’s pipeline and strategy. The successful pivotal trial of Olezarsen for patients with moderately high triglycerides has bolstered management’s confidence in the drug’s commercial potential, even though a statistically significant reduction in pancreatitis events would be an added benefit. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 9.66, providing ample resources for its development programs.
Ionis is also looking forward to the cardiovascular outcomes trial (CVOT) for eplontersen, which is expected to produce results in the second half of 2026. Additionally, the company’s partnership with Biogen (NASDAQ:BIIB) on an anti-tau ASO for Alzheimer’s disease is showing promise, with phase 2b data anticipated in 2026. Ionis is actively investing in blood-brain barrier (BBB) technology, specifically through TfR1 approaches, and may acquire more wholly owned targets through this partnership.
The launch of donidalorsen and the pivotal readout for the LP(a) program are slated for significant events in the fourth quarter of 2025 and the first half of 2026, respectively. Lastly, Ionis views its alpha-synuclein program as a potential surprise in its pipeline, with proof-of-concept data expected by the end of 2025. InvestingPro subscribers can access detailed financial health scores and additional analyst insights to better evaluate the company’s pipeline potential. The platform offers comprehensive Pro Research Reports covering over 1,400 US stocks, including deep-dive analysis of Ionis’s development programs and financial outlook.
In other recent news, Ionis Pharmaceuticals reported its first-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of -0.93 compared to the forecasted -1.08. The company achieved revenues of $132 million, slightly below the forecast of $136.69 million, but still marking a 10% year-over-year increase. Ionis also announced positive results from a Phase 3 trial of olezarsen, showing significant reductions in triglyceride levels, which could support a supplemental New Drug Application filing. Additionally, the company revealed the successful launch of its drug Tryngolza for familial chylomicronemia syndrome, contributing to robust sales and prompting H.C. Wainwright to raise Ionis’ stock price target to $50.00. Analysts at H.C. Wainwright are optimistic about Tryngolza’s potential approval for severe hypertriglyceridemia, which could further boost Ionis’ financial performance. Ionis’ management noted that they are not facing resistance from payers regarding Tryngolza’s pricing, which bodes well for future revenue prospects. The company increased its 2025 revenue guidance by over 20%, projecting between $650 million and $750 million, driven by strong product performance and recent licensing transactions. Ionis continues to focus on expanding its market presence with upcoming product launches anticipated to drive further growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.